4.6 Article

T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study

期刊

PLOS ONE
卷 13, 期 1, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0178167

关键词

-

资金

  1. intramural research program at the National Cancer Institute, Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch
  2. NATIONAL CANCER INSTITUTE [U01CA078527] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Background It is unknown why a minority of women fail to clear human papillomavirus (HPV) and develop precancer/cancer. Differences in T-cell receptor (TCR) repertoires may identify HPV16-infected women at highest-risk for progression to cancer. We conducted a proof-of-principle study nested within the Guanacaste HPV Natural History Study to evaluate the utility of next-generation sequencing for interrogating the TCR repertoires among women who cleared and failed to clear cervical HPV16. Methods TCR repertoires of women with HPV16-related intraepithelial neoplasia grade 3 or higher (CIN3+; n = 25) were compared to women who cleared an incident HPV16 infection without developing precancer/cancer (n = 25). TCR diversity (richness and evenness) and relative abundance (RA) of gene segment (V [n = 51], D [n = 2], J [n = 13]) usage was evaluated; receiver operating curve analysis assessed the ability to differentiate case-control status. Results TCR repertoire richness was associated with CIN3+ status (P = 0.001). Relative abundance (RA) of V-gene segments was enriched for associations between cases and controls. A single V-gene (TRBV6-7) was significantly associated with CIN3+ status (RA = 0.11%, 0.16%, among cases and controls, respectively, Bonferroni P = 0.0008). The estimated area under the curve using richness and V-gene segment RA was 0.83 (95% confidence interval: 0.73 +/- 0.90). Conclusions Substantial differences in TCR repertoire among women with CIN3+ compared to women who cleared infection were observed. Impact This is the first study to use next-generation sequencing to investigate TCR repertoire in the context of HPV infection. These findings suggest that women with HPV16-associated cervical lesions have significantly different TCR repertoires from disease-free women who cleared HPV16 infection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Opium use and risk of lung cancer: A multicenter case-control study in Iran

Hamideh Rashidian, Maryam Hadji, Mahin Gholipour, Ahmad Naghibzadeh-Tahami, Maryam Marzban, Elham Mohebbi, Roya Safari-Faramani, Mahdieh Bakhshi, Monireh Sadat Seyyedsalehi, Bayan Hosseini, Reza Alizadeh-Navaei, Habib Emami, Ali Akbar Haghdoost, Abbas Rezaianzadeh, Abdolvahab Moradi, Alireza Ansari-Moghaddam, Azim Nejatizadeh, Soodabeh ShahidSales, Alireza Rezvani, Mohammad Hasan Larizadeh, Farid Najafi, Hossein Poustchi, Mohammad Ali Mohagheghi, Paul Brennan, Elisabete Weiderpass, Joachim Schuz, Eero Pukkala, Neal D. Freedman, Paolo Boffetta, Reza Malekzadeh, Arash Etemadi, Afarin Rahimi-Movaghar, Farin Kamangar, Kazem Zendehdel

Summary: Opium use is strongly associated with an increased risk of lung cancer, particularly small cell carcinoma. Regular opium users have a 3.6-fold higher risk of developing lung cancer compared to non-users, with a dose-response relationship observed. Female opium users have a higher risk than male users. The risk is further increased for individuals who use both opium and tobacco.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Public, Environmental & Occupational Health

Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

Hilary A. Robbins, Karine Alcala, Elham Khodayari Moez, Florence Guida, Sera Thomas, Hana Zahed, Matthew T. Warkentin, Karl Smith-Byrne, Yonathan Brhane, David Muller, Xiaoshuang Feng, Demetrius Albanes, Melinda C. Aldrich, Alan A. Arslan, Julie Bassett, Christine D. Berg, Qiuyin Cai, Chu Chen, Michael P. A. Davies, Brenda Diergaarde, John K. Field, Neal D. Freedman, Wen-Yi Huang, Mikael Johansson, Michael Jones, Woon-Puay Koh, Stephen Lam, Qing Lan, Arnulf Langhammer, Linda M. Liao, Geoffrey Liu, Reza Malekzadeh, Roger L. Milne, Luis M. Montuenga, Thomas Rohan, Howard D. Sesso, Gianluca Severi, Mahdi Sheikh, Rashmi Sinha, Xiao-Ou Shu, Victoria L. Stevens, Martin C. Tammemaegi, Lesley F. Tinker, Kala Visvanathan, Ying Wang, Renwei Wang, Stephanie J. Weinstein, Emily White, David Wilson, Jian-Min Yuan, Xuehong Zhang, Wei Zheng, Christopher I. Amos, Paul Brennan, Mattias Johansson, Rayjean J. Hung

Summary: The INTEGRAL program aims to develop tools for optimizing LDCT lung cancer screening. It includes the Risk Biomarker and Nodule Malignancy projects, which investigate circulating protein markers for identifying individuals likely to benefit from screening and distinguishing benign versus malignant nodules. A total of 1161 and 1078 proteins were measured, and 21 proteins were selected for performance evaluation in the Risk Biomarker and Nodule Malignancy projects.

ANNALS OF EPIDEMIOLOGY (2023)

Article Oncology

Associations between serum glucose, insulin, insulin resistance and the risk of incident primary liver cancer or chronic liver disease mortality: a nested case-control study

Jian Yin, Neal D. Freedman, Yiwei Liu, Sanford M. M. Dawsey, Huan Yang, Philip R. R. Taylor, Liangyu Yin, Bin Liu, Jianfeng Cui, Jinhu Fan, Wen Chen, Youlin Qiao, Christian C. C. Abnet

Summary: This study found that serum insulin and HOMA-IR may be risk factors for the development of primary liver cancer (PLC) or chronic liver disease (CLD) death. In HBV-positive patients, glucose was also associated with an increased risk of these diseases.

BRITISH JOURNAL OF CANCER (2023)

Article Multidisciplinary Sciences

Inflated expectations: Rare-variant association analysis using public controls

Jung Kim, Danielle M. Karyadi, Stephen W. Hartley, Bin Zhu, Mingyi Wang, Dongjing Wu, Lei Song, Gregory T. Armstrong, Smita Bhatia, Leslie L. Robison, Yutaka Yasui, Brian Carter, Joshua N. Sampson, Neal D. Freedman, Alisa M. Goldstein, Lisa Mirabello, Stephen J. Chanock, Lindsay M. Morton, Sharon A. Savage, Douglas R. Stewart

Summary: The use of publicly available sequencing datasets as controls in rare variant disease association studies can increase the risk of false-positive discoveries. This study systematically investigated the factors that contribute to false-positive discoveries using both public controls and datasets sequenced in their own laboratory. The results showed that using the same variant caller and filtering pipelines significantly reduced the inflation of test statistics. However, differences in library prep kits and sequencers as well as joint vs. separate variant-calling of cases and controls did not affect the false-positive rate. This highlights the risks associated with using public controls and suggests the potential of cloud-based computing to mitigate these issues.

PLOS ONE (2023)

Article Multidisciplinary Sciences

GWAS Explorer: an open-source tool to explore, visualize, and access GWAS summary statistics in the PLCO Atlas

Mitchell J. Machiela, Wen-Yi Huang, Wendy Wong, Sonja I. Berndt, Joshua Sampson, Jonas De Almeida, Mustapha Abubakar, Jada Hislop, Kai-Ling Chen, Casey Dagnall, Norma Diaz-Mayoral, Mary Ferrell, Michael Furr, Alex Gonzalez, Belynda Hicks, Aubrey K. Hubbard, Amy Hutchinson, Kevin Jiang, Kristine Jones, Jia Liu, Erikka Loftfield, Jennifer Loukissas, Jerome Mabie, Shannon Merkle, Eric Miller, Lori M. Minasian, Ellen Nordgren, Brian Park, Paul Pinsky, Thomas Riley, Lorena Sandoval, Neeraj Saxena, Aurelie Vogt, Jiahui Wang, Craig Williams, Patrick Wright, Meredith Yeager, Bin Zhu, Claire Zhu, Stephen J. Chanock, Montserrat Garcia-Closas, Neal D. Freedman

Summary: The PLCO Cancer Screening Trial is a prospective cohort study that developed the PLCO Atlas Project, a large resource for GWAS. Genotyping was performed on participants with available DNA, and GWAS were conducted using a custom pipeline. The PLCO Atlas GWAS Explorer website, with APIs and SDKs, allows for exploration, visualization, and open data access. It currently hosts association data for 90 traits and >78 million genomic markers, focusing on cancer-related phenotypes. The PLCO Atlas is a FAIR resource for cancer research and genetic epidemiology.

SCIENTIFIC DATA (2023)

Article Oncology

Biomarkers of Tobacco Carcinogenesis in Diverse Populations: Challenges and Opportunities

Arash Etemadi, Christian C. Abnet, Sanford M. Dawsey, Neal D. Freedman

Summary: Biomarkers can provide unique information about cancer risk factors by measuring the internal dose of carcinogens. Smoke-related biomarkers, including tobacco-specific biomarkers and those from exposure to tobacco and non-tobacco pollutants, are commonly studied in relation to cancer. Biomonitoring is superior to self-reported exposure assessment and will continue to be essential to cancer research.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Article Oncology

Stressful Life Events, Social Support, and Incident Breast Cancer by Estrogen Receptor Status

Wayne R. Lawrence, Jasmine A. McDonald, Faustine Williams, Meredith S. Shiels, Neal D. Freedman, Ziqiang Lin, Jared W. Magnani

Summary: Chronic stress is hypothesized to be associated with breast cancer, but previous studies have shown mixed results. This study examined the association between self-reported stressful life events and incident breast cancer in postmenopausal women, taking into account estrogen receptor (ER) status and social support. The results showed that there was no relationship between stressful life events and ER-positive breast cancer, but there was an increased risk of ER-negative breast cancer in women with higher levels of stressful life events. This association was stronger in widowed women. Social support did not modify the relationship between stressful life events and ER-negative breast cancer.

CANCER PREVENTION RESEARCH (2023)

Article Oncology

Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Vicky C. C. Chang, Jongeun Rhee, Sonja I. I. Berndt, Steven C. C. Moore, Neal D. D. Freedman, Rena R. R. Jones, Debra T. T. Silverman, Gretchen L. L. Gierach, Jonathan N. N. Hofmann, Mark P. P. Purdue

Summary: In this nested case-control study, prediagnostic serum levels of PFOS and PFOA were found to be associated with breast cancer risk, particularly for hormone receptor-positive tumors, providing evidence of a possible positive association.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Cancer mortality rates by racial and ethnic groups in the United States, 2018-2020

Anika T. Haque, Amy Berrington de Gonzalez, Yingxi Chen, Emily A. Haozous, Maki Inoue-Choi, Wayne R. Lawrence, Jennifer K. McGee-Avila, Anna M. Napoles, Eliseo J. Perez-Stable, Kekoa Taparra, Jacqueline B. Vo, Neal D. Freedman, Meredith S. Shiels

Summary: The study estimated cancer death rates among different racial and ethnic groups in the United States from 2018 to 2020. The results found significant disparities in cancer death rates, with the highest rates observed among Black individuals and Native Hawaiian and Pacific Islander (NHPI) individuals. Separating NHPI and Asian individuals revealed large differences in cancer mortality between the two groups that were previously combined in vital statistics data.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools

Xiaoshuang Feng, Wendy Yi-Ying Wu, Justina Ucheojor Onwuka, Zahra Haider, Karine Alcala, Karl Smith-Byrne, Hana Zahed, Florence Guida, Renwei Wang, Julie K. Bassett, Victoria Stevens, Ying Wang, Stephanie Weinstein, Neal D. Freedman, Chu Chen, Lesley Tinker, Therese Haugdahl Nost, Woon-Puay Koh, David Muller, Sandra M. Colorado-Yohar, Rosario Tumino, Rayjean J. Hung, Christopher Amos, Xihong Lin, Xuehong Zhang, Alan A. Arslan, Maria-Jose Sanchez, Elin Pettersen Sorgjerd, Gianluca Severi, Kristian Hveem, Paul Brennan, Arnulf Langhammer, Roger L. Milne, Jian-Min Yuan, Beatrice Melin, Mikael Johansson, Hilary A. Robbins, Mattias Johansson

Summary: This study aimed to develop a proteomics-based risk model for lung cancer and compare its performance with a smoking-based risk model and a commercially available autoantibody biomarker test. We conducted a case-control study in 6 prospective cohorts, involving 624 lung cancer participants and 624 smoking-matched cancer free participants. The protein-based risk model showed promise in predicting incident lung cancer and outperformed the standard risk prediction model and the commercialized EarlyCDT-Lung.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Biochemistry & Molecular Biology

Genetically adjusted PSA levels for prostate cancer screening

Linda Kachuri, Thomas J. Hoffmann, Yu Jiang, Sonja I. Berndt, John P. Shelley, Kerry R. Schaffer, Mitchell J. Machiela, Neal D. Freedman, Wen-Yi Huang, Shengchao A. Li, Ryder Easterlin, Phyllis J. Goodman, Cathee Till, Ian Thompson, Hans Lilja, Stephen K. Van Den Eeden, Stephen J. Chanock, Christopher A. Haiman, David V. Conti, Robert J. Klein, Jonathan D. Mosley, Rebecca E. Graff, John S. Witte

Summary: Prostate-specific antigen (PSA) screening for prostate cancer remains controversial due to overdiagnosis and overtreatment. However, accounting for genetic determinants of PSA variation may improve screening accuracy.

NATURE MEDICINE (2023)

Article Oncology

Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047

Meredith S. Shiels, Stanley Lipkowitz, Nicole G. Campos, Mark Schiffman, John T. Schiller, Neal D. Freedman, Amy Berrington de Gonzalez

Summary: President Biden and First Lady Dr. Biden have reignited the Cancer Moonshot with the goal of reducing age-standardized cancer mortality rates by at least 50% in the United States over the next 25 years. From 2000 to 2019, overall cancer death rates declined, driven by significant decreases in lung, colorectal, and breast cancer mortality. However, progress for other cancer types was less promising, highlighting the need for new strategies. Achieving the Moonshot goal requires maintaining or accelerating progress in controlling lung, colorectal, and breast cancer deaths, and developing new approaches for prostate, liver, pancreatic, and other cancers.

CANCER DISCOVERY (2023)

Meeting Abstract Oncology

Association of genetic ancestry with lung-cancer risk in White and Black eversmokers.

Courtney D. Dill, Dontray Trump, Rebecca Landy, Li Cheung, Wen-Yi Huang, Sonja Berndt, Neal Freedman, Hormuzd Katki

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Meeting Abstract Oncology

Association of genetic ancestry with lung-cancer risk in White and Black ever-smokers

Courtney D. Dill, Dontray Trump, Rebecca Landy, Li Cheung, Wen-Yi Huang, Sonja Berndt, Neal Freedman, Hormuzd Katki

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Meeting Abstract Oncology

Association of genetic ancestry with lung-cancer risk in White and Black ever-smokers

Courtney D. Dill, Dontray Trump, Rebecca Landy, Li Cheung, Wen-Yi Huang, Sonja Berndt, Neal Freedman, Hormuzd Katki

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

暂无数据